Harshabad Singh, Pranshu Sahgal, Kevin Kapner, Steven M Corsello, Hersh Gupta, Rahul Gujrathi, Yvonne Y Li, Andrew D Cherniack, Raquelle El Alam, Joseph Kerfoot, Elizabeth Andrews, Annette Lee, Chetan Nambiar, Alison M Hannigan, Joshua Remland, Lauren Brais, Meghan E Leahy, Douglas A Rubinson, Benjamin L Schlechter, Matthew Meyerson, Yanan Kuang, Cloud P Paweletz, Jessica K Lee, Julia C F Quintanilha, Andrew J Aguirre, Kimberly J Perez, Brandon M Huffman, Humberto Rossi, Thomas A Abrams, Sheheryar Kabraji, Livio Trusolino, Andrea Bertotti, Ewa T Sicinska, Aparna R Parikh, Brian M Wolpin, Alexa B Schrock, Marios Giannakis, Kimmie Ng, Jeffrey A Meyerhardt, Jason L Hornick, Nilay S Sethi, James M Cleary
PURPOSE: ERBB2 amplified colorectal cancer (CRC) is a distinct molecular subtype with expanding treatments. Implications of concurrent oncogenic RAS/RAF alterations are not known. EXPERIMENTAL DESIGN: Dana-Farber and Foundation Medicine Inc. CRC cohorts with genomic profiling were used to identify ERBB2 amplified cases (Dana-Farber, n = 47/2,729 [1.7%]; FMI, n = 1857/49,839 [3.7%]). Outcomes of patients receiving HER2-directed therapies are reported (Dana-Farber, n = 9; Flatiron Health-Foundation Medicine clinicogenomic database, FH-FMI CGDB, n = 38)...
February 12, 2024: Clinical Cancer Research